Precision traffic control
With series A, Perthera wants to become traffic control for precision medicine
Following its July $8.7 million series A funding round, Perthera Inc. is building up its precision medicine information delivery business as it moves toward expanding access to physicians and patients worldwide. The company is pursuing an IT approach to diagnostic management and delivery that gives doctors access to expert guidance on which tests to order and how to interpret results.
Emanuel Petricoin, Perthera's co-founder and CSO, told BioCentury he and fellow co-founder Dendy Young formed the company in 2011 when they sensed the opportunity in precision medicine was starting to take off. The "inflection point," he said, was "the commoditization of molecular diagnostics - a proliferation of commercially available, accredited laboratories that can run genomics, proteomics and phosphoproteomics."...